Loading clinical trials...
Loading clinical trials...
Randomized Phase 2b Study of Safety And Efficacy Of TVI-Brain-1 Combined With Conformal Radiotherapy And Temozolomide Vs Standard Therapy In Newly Diagnosed MGMT Negative Glioblastoma Multiforme (GBM)
Conditions
Interventions
TVI-Brain-1
Standard of Care
+2 more
Locations
8
United States
Center for Neurosciences
Tucson, Arizona, United States
Cedar-Sanai Medical Center
Los Angeles, California, United States
University of Southern California Keck School of Medicine
Los Angeles, California, United States
Moffitt Cancer Center
Tampa, Florida, United States
Aaron Mammoser
Atlanta, Georgia, United States
University of Kansas Medical Center
Kansas City, Kansas, United States
Start Date
September 15, 2023
Primary Completion Date
December 1, 2026
Completion Date
March 1, 2027
Last Updated
July 1, 2025
NCT06146725
NCT04968366
NCT07464925
NCT06193174
NCT04869449
NCT04222309
Lead Sponsor
TVAX Biomedical
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions